Literature DB >> 22791901

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

David A Wolk1, Zheng Zhang, Sanaa Boudhar, Christopher M Clark, Michael J Pontecorvo, Steven E Arnold.   

Abstract

BACKGROUND: Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11.
METHODS: Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period.
RESULTS: Both ligands displayed highly significant group discrimination and correlation of regional uptake.
CONCLUSION: These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791901      PMCID: PMC4479493          DOI: 10.1136/jnnp-2012-302548

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  PET imaging of amyloid deposition in patients with mild cognitive impairment.

Authors:  Anton Forsberg; Henry Engler; Ove Almkvist; Gunnar Blomquist; Göran Hagman; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Neurobiol Aging       Date:  2007-05-11       Impact factor: 4.673

3.  Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.

Authors:  Cyrus A Raji; James T Becker; Nicholas D Tsopelas; Julie C Price; Chester A Mathis; Judith A Saxton; Brian J Lopresti; Jessica A Hoge; Scott K Ziolko; Steven T DeKosky; William E Klunk
Journal:  J Neurosci Methods       Date:  2008-05-16       Impact factor: 2.390

Review 4.  Update on amyloid imaging: from healthy aging to Alzheimer's disease.

Authors:  David A Wolk; William Klunk
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

5.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

6.  Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

Authors:  Ville Leinonen; Irina Alafuzoff; Sargo Aalto; Timo Suotunen; Sakari Savolainen; Kjell Någren; Tero Tapiola; Tuula Pirttilä; Jaakko Rinne; Juha E Jääskeläinen; Hilkka Soininen; Juha O Rinne
Journal:  Arch Neurol       Date:  2008-08-11

7.  Amyloid imaging in mild cognitive impairment subtypes.

Authors:  David A Wolk; Julie C Price; Judy A Saxton; Beth E Snitz; Jeffrey A James; Oscar L Lopez; Howard J Aizenstein; Ann D Cohen; Lisa A Weissfeld; Chester A Mathis; William E Klunk; Steven T De-Kosky; Steven T DeKoskym
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

8.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

9.  In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.

Authors:  M A Burack; J Hartlein; H P Flores; L Taylor-Reinwald; J S Perlmutter; N J Cairns
Journal:  Neurology       Date:  2010-01-05       Impact factor: 9.910

10.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

View more
  38 in total

1.  Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.

Authors:  P Payoux; J Delrieu; A Gallini; D Adel; A S Salabert; A Hitzel; C Cantet; M Tafani; D De Verbizier; J Darcourt; Ph Fernandez; J Monteil; I Carrié; T Voisin; S Gillette-Guyonnet; M Pontecorvo; B Vellas; S Andrieu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-08       Impact factor: 9.236

2.  Impact of Amyloid PET Imaging in the Memory Clinic: A Systematic Review and Meta-Analysis.

Authors:  Yat-Fung Shea; Warren Barker; Maria T Greig-Gusto; David A Loewenstein; Ranjan Duara; Steven T DeKosky
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

4.  Amyloid imaging in depression: a predictor of Alzheimer's disease?

Authors:  Valle Camacho; Alberto Lleó
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04       Impact factor: 9.236

Review 5.  Molecular imaging of Alzheimer disease pathology.

Authors:  K Kantarci
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-06       Impact factor: 3.825

Review 6.  Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.

Authors:  Nasim Sheikh-Bahaei; Seyed Ahmad Sajjadi; Aimee L Pierce
Journal:  Curr Treat Options Neurol       Date:  2017-11-14       Impact factor: 3.598

Review 7.  Amyloid Imaging: Poised for Integration into Medical Practice.

Authors:  Keshav Anand; Marwan Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

8.  Focal hemosiderin deposits and β-amyloid load in the ADNI cohort.

Authors:  Kejal Kantarci; Jeffrey L Gunter; Nirubol Tosakulwong; Stephen D Weigand; Matthew S Senjem; Ronald C Petersen; Paul S Aisen; William J Jagust; Michael W Weiner; Clifford R Jack
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

9.  Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Authors:  Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Maria C Carrillo; Dean M Hartley; Saima Hedrick; Virginia Pappas; William H Thies
Journal:  Alzheimers Dement       Date:  2013-01       Impact factor: 21.566

Review 10.  Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.

Authors:  Juan Carlos Polanco; Chuanzhou Li; Liviu-Gabriel Bodea; Ramon Martinez-Marmol; Frederic A Meunier; Jürgen Götz
Journal:  Nat Rev Neurol       Date:  2017-12-15       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.